Delft, Netherlands – September 15, 2026 -- AdJane Biosciences has published a technical white paper detailing a strategy to add a proprietary mucosal-immunity booster to established intramuscular respiratory vaccine franchises, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.